aDepartment of Medicine, 1st Faculty of Medicine, Military University Hospital b1st Faculty of Medicine, Institute of General Practice, Charles University cCenter for Applied Genomics of Solid Tumors, Genomac Research Institute dNational Reference Centre, Prague eInstitute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
Eur J Cancer Prev. 2014 Jan;23(1):18-26. doi: 10.1097/CEJ.0b013e328364f203.
The incidence and mortality of colorectal cancer (CRC) in the Czech Republic is significant. The National CRC Screening Program started in 2000 and was further enhanced in 2009. In 2010, the European Guidelines were introduced. The aim of the present trend study was to evaluate the quality of the Czech National Colorectal Cancer Screening Program using early performance and long-term impact indicators. The screening program has been assessed using data from three sources: the Czech National Cancer Registry, the Czech National Reference Centre, and the Czech CRC Screening Registry. The data were compared with a set of recommended quality control indicators. Between 2006 and 2010, a total of 1 881 299 fecal occult blood tests were performed, of which 87 397 were positive (4.6%). Until 2011, a total of 68 527 fecal occult blood test follow-up colonoscopies were performed. In addition, between 2009 and 2011, a total of 10 309 screening colonoscopies were performed. As a result, a total of 25 255 adenomas (32.0% rate) and 3379 CRCs (4.3% rate) were detected. A trend of cancer detection in earlier stages has been observed. The overall program coverage has increased to 22.7% of the target population in 2010. The majority of European guidelines' quality indicators for nonpopulation-based programs were implemented in the Czech National CRC Screening program. An improvement in program management was accompanied by an increase in coverage as well as other performance indicators.
捷克共和国结直肠癌（CRC）的发病率和死亡率较高。国家 CRC 筛查计划于 2000 年启动，并于 2009 年进一步加强。2010 年引入了欧洲指南。本趋势研究的目的是使用早期绩效和长期影响指标评估捷克国家结直肠癌筛查计划的质量。该筛查计划使用来自三个来源的数据进行评估：捷克国家癌症登记处、捷克国家参考中心和捷克 CRC 筛查登记处。将数据与一组推荐的质量控制指标进行了比较。2006 年至 2010 年期间，共进行了 1 881 299 次粪便潜血试验，其中 87 397 次呈阳性（4.6%）。截至 2011 年，共进行了 68 527 次粪便潜血试验随访结肠镜检查。此外，2009 年至 2011 年期间，共进行了 10 309 次筛查结肠镜检查。结果共发现 25 255 个腺瘤（32.0%的检出率）和 3379 例 CRC（4.3%的检出率）。已经观察到癌症检出较早阶段的趋势。2010 年，该计划的总体覆盖率已增加到目标人群的 22.7%。大多数基于非人群的计划的欧洲指南质量指标都在捷克国家 CRC 筛查计划中得到了实施。随着覆盖范围的增加和其他绩效指标的提高，计划管理得到了改善。
